Drug development, commercial strategy, device innovation, and AI in the pipeline, covered for the teams bringing therapies and technologies to market.
Medicare's third negotiation cycle is the first to reach physician-administered drugs, which turns a pharmacy benefit story into a provider revenue story for hospitals, infusion centers and oncology practices.
Read full story
The White House's newest round of most favored nation pricing agreements covers nine midsized manufacturers, shifting exposure toward specialty and rare disease products with no easy substitute.
Pharma's headline AI discovery partnerships now run past $1B, but cash at signing is typically $30M to $50M. Health system and payer leaders should plan for the pipeline, not the press release.
Twenty-six companies now cover 89% of the branded drug market under voluntary MFN agreements, but SEC filings show three-year terms with sunset dates buyers cannot see.
The stories on this page, distilled into one email for healthcare leaders. Free, every week.
Unsubscribe anytime. We treat your data under a documented consent and outreach model.
